GRAF JAMES A (Chief Executive Officer) purchased 2913.0% of their position (670.00 shares) of NKGEN BIOTECH, INC. on the open market
Open‑market purchase worth $2.2K — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 12/5/2023ACC: 0001209191-23-057369
Officer10% Owner· Chief Executive Officer
Since May 2021
+670.00
Net shares
Net buyer
$2.2K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
670.00 acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+220.00
Price / share
$3.35
Trade value
$737.00
% of position
956.5%
12/1/2023
23.00→243.00
Common Stock
Direct
Shares
+450.00
Price / share
$3.19
Trade value
$1.44K
% of position
185.2%
12/4/2023
243.00→693.00
Total
Net shares
+670.00
Net value
$2.17K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/1/2023 | P · Purchase | +220.00 | $3.35 | $737.00 | 956.5% | 23.00 | 243.00 |
| Common Stock Direct | 12/4/2023 | P · Purchase | +450.00 | $3.19 | $1.44K | 185.2% | 243.00 | 693.00 |
| Total | +670.00 | $2.17K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned2.44M
Total
2.44M indirect2.44M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 2.44M | Indirect |
| Total | 2.44M | 2.44M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported